Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Bowel Disease (IBD) Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MAdCAM1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MAdCAM1 ECD-Fc Fusion Protein High purity (>95%), Endotoxin controlled (<1.0 EU/μg). Sequence Verified. HEK293 expressed for native glycosylation. |
View MAdCAM1 Products |
| Gene Delivery | MAdCAM1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based adhesion assays. |
View MAdCAM1 Products |
| Benchmark Ab | Anti-MAdCAM1 Recombinant Antibody Sequence derived from Ontamalimab. Recombinant positive control for binding and blocking assays. |
View MAdCAM1 Products |
| Validator | MAdCAM1 siRNA Set Target-specific knockdown verification in primary endothelial cells. |
View MAdCAM1 Products |
| Related Target A | Integrin alpha 4 (ITGA4) Forms heterodimer with ITGB7; the primary physiological receptor for MAdCAM1. |
View ITGA4 Products |
| Related Target B | Integrin beta 7 (ITGB7) Partner subunit of ITGA4; critical for mucosal homing assay validation. |
View ITGB7 Products |
| Related Target C | VCAM1 Critical homolog for counter-screening to ensure gut-selective adhesion blocking. |
View VCAM1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Cynomolgus, and Mouse MAdCAM1 ortholog proteins available with >95% purity verified by SDS-PAGE |
| Subfamily counter screening (VCAM1/ICAM1) | Homolog panel proteins strictly sequence-verified and quality-controlled to ensure zero cross-reactivity |
| Lack of Controls | Ontamalimab-biosimilar benchmark antibodies included to establish reliable assay baselines |
| False Positives in Adhesion Assays | Sequence-verified siRNA pool included for target-specific knockdown validation |
Live MAdCAM1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MAdCAM1 therapeutics is intensifying, with major players shifting focus from systemic immunosuppression to gut-selective anti-inflammatory pathways. As first-generation integrin inhibitors (such as Vedolizumab targeting alpha-4-beta-7) prove block-buster efficacy, targeting the endothelial ligand MAdCAM1 directly represents the next wave of R&D. This approach aims to eliminate systemic side effects (such as PML risks associated with non-selective integrin blockers) and maximize mucosal healing in Crohn's disease and Ulcerative Colitis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Takeda (Ontamalimab), Pfizer | Ulcerative Colitis, Crohn's Disease | Ligand-receptor blocking assay (Needs high-purity MAdCAM1 ECD-Fc and ITGA4/ITGB7 complex) |
| Bispecific / Multi-specific | Innovative Biotechs | Refractory IBD | Dual-targeting validation (Needs cross-reactive orthologs and high-affinity benchmark control) |
| Small Molecule / Peptide | Gilead, Moricodia | Oral IBD therapies | Competitive binding inhibition (Needs stable, HEK293-expressed MAdCAM1 recombinant proteins) |